Vertex Pharmaceuticals Inc (VRTX) Com Stk

Sell:$468.72Buy:$468.97$10.68 (2.23%)

NASDAQ:0.22%
Market closed | Prices delayed by at least 15 minutes
Sell:$468.72
Buy:$468.97
Change:$10.68 (2.23%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$468.72
Buy:$468.97
Change:$10.68 (2.23%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).

Key people

Jeffrey M. Leiden
Executive Chairman of the Board
Reshma Kewalramani
President, Chief Executive Officer, Director
Charles F. Wagner
Chief Financial Officer, Chief Operating Officer, Executive Vice President
David M. Altshuler
Executive Vice President, Chief Scientific Officer
E. Morrow Atkinson
Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Science and Manufacturing Operations
Jonathan Biller
Executive Vice President, Chief Legal Officer
Carmen Bozic
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Duncan Mckechnie
Executive Vice President, Chief Commercial Officer
Amit K. Sachdev
Executive Vice President, Chief Patient and External Affairs Officer
Ourania Tatsis
Executive Vice President, Chief Regulatory and Quality Officer
Bruce I. Sachs
Lead Independent Director
Sangeeta N. Bhatia
Independent Director
Lloyd A. Carney
Independent Director
Alan Garber
Independent Director
Michel Lagarde
Independent Director
Click to see more

Key facts

  • EPIC
    VRTX
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US92532F1003
  • Market cap
    $123.00bn
  • Employees
    6,100
  • Shares in issue
    256.80m
  • Exchange
    NASDAQ
  • Index
    S&P 500, NASDAQ 100 Index, TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.